Tone mix
Week by week 52 weeks
Share of Viking Therapeutics, Inc's 213 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Jun 15, 2026 · tone +100Viking Therapeutics (VKTX) Offers Potential With VK2735 Market Opportunity+70
- Week of Feb 23, 2026 · tone +99Why Viking Therapeutics Stock Is Up More Than 9% Today+69
- Week of Aug 10, 2026 · tone -50Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?-65
- Week of Oct 12, 2026 · tone +99Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.+60
- Week of Mar 16, 2026 · tone -33Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics-59
- Week of Mar 2, 2026 · tone -21Raymond James Lowers Viking Therapeutics, Inc. (VKTX) Price Target Amid Optimistic Clinical Initiative Outlook-53
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Viking Therapeutics, Inc in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 7 | +14 |
| Last 30 sessions | 27 | +46 |
| Last 90 sessions | 94 | +30 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Wednesday, November 4, 2026
2 headlines, average tone -48: 0 positive, 1 neutral and 1 negative. Showing all 2.
- www.aol.com · 2 outletsViking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.Negative
- www.prnewswire.com · 1 outletViking Therapeutics to Participate at Upcoming Investor ConferencesNeutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors. | www.aol.com | 2 | Negative |
| Viking Therapeutics to Participate at Upcoming Investor Conferences | www.prnewswire.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, November 2, 2026
2 headlines, average tone +50: 1 positive, 1 neutral and 0 negative. Showing all 2.
- www.aol.com · 3 outletsUBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.Positive
- www.dailypolitical.com · 1 outletViking Therapeutics Q3 Earnings Call HighlightsNeutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case. | www.aol.com | 3 | Positive |
| Viking Therapeutics Q3 Earnings Call Highlights | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 29, 2026
3 headlines, average tone +32: 1 positive, 2 neutral and 0 negative. Showing all 3.
- seekingalpha.com · 1 outletViking outlines ~$100M average quarterly cash usage as Phase III SUNRISE and VANQUISH advance (NASDAQ:VKTX)Positive
- www.fool.com · 1 outletViking (VKTX) Q3 2026 Earnings Call TranscriptNeutral
- www.prnewswire.com · 1 outletViking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNeutral
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Viking outlines ~$100M average quarterly cash usage as Phase III SUNRISE and VANQUISH advance (NASDAQ:VKTX) | seekingalpha.com | 1 | Positive |
| Viking (VKTX) Q3 2026 Earnings Call Transcript | www.fool.com | 1 | Neutral |
| Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update | www.prnewswire.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 26, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.aol.com · 1 outletWhy Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28 | www.aol.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 22, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.prnewswire.com · 1 outletViking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026 | www.prnewswire.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Viking Therapeutics, Inc, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.